免疫组化法检测肝癌组织Twist表达的临床意义

摘要/Abstract

摘要： 目的探讨免疫组化法检测肝癌组织Twist表达的临床意义。方法 2013年1月至2017年1月钦州市第二人民医院肝细胞癌手术切除临床标本136例,其中配对癌旁肝组织(距癌组织边缘＜3 cm)85例,采用免疫组化法检测肝癌组织及癌旁肝组织中Twist蛋白表达情况,分析Twist蛋白表达与肝细胞癌患者临床病理参数及预后的关系。结果 Twist蛋白阳性着色主要位于细胞质,表现为棕黄色颗粒,呈片状、巢状或弥漫性分布。癌组织中Twist蛋白阳性表达率为66.2%,显著高于癌旁肝组织的5.9%(P<0.05)。136例癌组织标本中有90例Twist蛋白阳性表达,46例Twist蛋白阴性表达。Twist阳性组病理分级为Ⅲ～Ⅳ级、TNM分期为Ⅲ～Ⅳ期、肿瘤细胞分化程度为低分化、包膜不完整和血管侵袭所占比例分别为45.6%、46.7%、46.7%、41.1%和35.6%,显著高于Twist阴性组的23.9%、28.3%、26.1%、19.6%和17.4%(P<0.05)。Twist阳性组年龄、性别、肿瘤大小、血清甲胎蛋白水平较Twist阴性组比较差异无统计学意义(P>0.05)。Twist阳性组患者与阴性组患者3年累积生存率分别为57.8%和65.2%,差异无统计学意义(P>0.05)。结论 Twist过度表达可能与肝细胞癌的发生、发展及预后密切相关,有望成为治疗肝细胞癌的一个靶基因,临床应引起足够重视。

关键词: 免疫组化法, 肝细胞癌, Twist

Abstract: Objective To explore the clinical significance of the expression of Twist in liver cancer tested by immunohistochemistry. Methods There were 136 clinical specimens of primary hepatocellular carcinoma (HCC) tissues from January 2013 to January 2017 in our hospital analyzed in the study, 85 of which contained paracarcinomatous tissues (< 3 cm away from HCC). The expression levels of Twist in HCC tissues and paracarcinomatous tissues were detected by immunohistochemistry, and the relationship of Twist expression to clinicopathological parameters and prognosis of HCC patients was analyzed. Results The positive staining area of Twist protein was mainly located in cytoplasm, which was distributed in patches, nests or a diffuse manner as brownish yellow granules. The positive expression rate of Twist protein in cancer tissues was 66.2%, significantly higher than 5.9% in paracarcinomatous tissues (P<0.05). Among 136 cancer tissue samples, 90 were Twist protein positive and 46 were negative. In Twist positive group, the rates of pathologic stage Ⅲ ~ Ⅳ, TNM stage Ⅲ ~ Ⅳ, poorly differentiated tumor cells, incomplete capsule and vascular invasion were 45.6%, 46.7%, 46.7%, 41.1% and 35.6%, significantly higher than 23.9%, 28.3%, 26.1%, 19.6% and 17.4% in Twist negative group (P<0.05). There was no significant difference in age, sex, tumor size or serum alpha-fetoprotein level between Twist positive and negative groups (P>0.05). And 3-year survival rate was 57.8% in Twist positive group and 65.2% in negative group, with no significant difference between. Conclusion Twist overexpression may be closely related to the occurrence, development and prognosis of primary HCC. And Twist is expected to a therapeutic target for primary HCC, which deserves more attention in clinical practice.

Key words: Immunohistochemistry, Hepatocellular carcinoma, Twist

韦小芳, 欧传话, 李绍龙, 毛小玲. 免疫组化法检测肝癌组织Twist表达的临床意义[J]. 肝脏, 2021, 26(3): 281-283.

WEI Xiao-fang, OU Chuan-hua, LI Shao-long, MAO Xiao-ling. The clinical significance of the expression of Twist in liver cancer tested by immunohistochemistry[J]. Chinese Hepatolgy, 2021, 26(3): 281-283.

参考文献

[1] Yang JD, Ahmed Mohammed H, Harmsen WS , et al. Recent trends in the epidemiology of hepatocellular carcinoma in olmsted county, minnesota: a US population-based study. J Clin Gastroenterol, 2017, 51:742-748.
[2] 张海涛. 多层螺旋CT平扫及三期动态增强扫描对肝细胞癌的诊断价值研究. 中国CT和MRI杂志, 2018, 16:86-88.
[3] 王卫东, 侯思楠, 陈栋, 等. 肝动脉化疗栓塞联合索拉菲尼治疗肝细胞肝癌的疗效及其预后分析. 中华肝脏病杂志, 2018, 26:690-693.
[4] 李威, 杨学刚, 杨浩, 等. 肝动脉化疗栓塞联合射频消融治疗直径3.1~5.0 cm肝细胞癌的疗效评价. 中华普通外科杂志, 2019, 34:240-243.
[5] 肖二卫, 陶连元, 魏艳奎,等. 荧光腹腔镜在肝细胞癌根治性切除术中的应用. 中华肝胆外科杂志, 2019, 25:87-89.
[6] 刘爱祥, 王海清, 薄文滔, 等. 肝细胞癌肝切除术的临床疗效及预后因素分析. 中华消化外科杂志, 2019, 18:368-374.
[7] 朱思聪, 谭文亮, 商昌珍, 等. 分子靶向药物治疗肝细胞癌的临床应用进展. 中华实验外科杂志, 2018, 35:1775-1777.
[8] 李保国. 肝细胞癌预后相关细胞分子生物标志物研究进展. 国际肿瘤学杂志, 2015, 42:395-398.
[9] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版). 中华肝脏病杂志, 2012, 20:929-946.
[10] 李伟, 宋燕州, 李锴. BMP7在肝细胞癌中的表达及其与Twist、E-cadherin及N-cadherin的关系探讨. 医学信息, 2018, 31:72-73.
[11] 薛栋, 王妮, 徐怀勇,等. TRIM59、Twist及E-cadherin在肝癌中的表达及临床意义. 实用医学杂志, 2017, 33:1453-1456.
[12] Wang Y , Sun B , Zhao X . Twist1-related miR-26b-5p suppresses epithelial-mesenchymal transition, migration and invasion by targeting SMAD1 in hepatocellular carcinoma. Oncotarget, 2016, 7:24383-24401.
[13] Yu X , Zheng Y , Zhu X , et al. Osteopontin promotes hepatocellular carcinoma progression via the PI3K/AKT/Twist signaling pathway. Oncol Lett, 2018, 16:5299-5308.
[14] Zhao Y , Jin X , Li N , et al. Expression and clinical significance of ALDH1 and Twist in gastric adenocarcinoma. Sichuan Da Xue Xue Bao Yi Xue Ban, 2016, 47:54-59.
[15] Zhang C , Guo F , Xu G , et al. STAT3 cooperates with Twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells. Oncol Rep, 2015, 33:1872-82.
[16] Nagai T , Arao T , Nishio K , et al. Impact of tight junction protein ZO-1 and Twist expression on postoperative survival of patients with hepatocellular carcinoma. Dig Dis, 2016, 34:702-707.